QURE

QURE

USD

uniQure N.V. Ordinary Shares

$30.440-0.370 (-1.201%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
هولندا

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$30.810

الأعلى

$32.490

الأدنى

$28.500

الحجم

8.90M

أساسيات الشركة

القيمة السوقية

1.9B

الصناعة

التكنولوجيا الحيوية

البلد

Netherlands

إحصاءات التداول

متوسط الحجم

3.75M

البورصة

NMS

العملة

USD

نطاق 52 أسبوعاً

الأدنى $5.35الحالي $30.440الأعلى $71.5

أخبار ذات صلة

GlobeNewswire

uniQure N.V. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (QURE)

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. ("uniQure" or the "Company") (NASDAQ:QURE). The investigation concerns whether the

عرض المزيد
Analyst Upgrades

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.

عرض المزيد
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
Analyst Upgrades

Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $38

Goldman Sachs analyst Salveen Richter maintains uniQure with a Neutral and lowers the price target from $56 to $38.

عرض المزيد
Goldman Sachs Maintains Neutral on uniQure, Lowers Price Target to $38
Analyst Upgrades

RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $45

RBC Capital analyst Luca Issi maintains uniQure with a Outperform and lowers the price target from $65 to $45.

عرض المزيد
RBC Capital Maintains Outperform on uniQure, Lowers Price Target to $45
Analyst Upgrades

William Blair Downgrades uniQure to Market Perform

William Blair analyst Sami Corwin downgrades uniQure from Outperform to Market Perform.

عرض المزيد
William Blair Downgrades uniQure to Market Perform
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on uniQure, Lowers Price Target to $70

HC Wainwright & Co. analyst Patrick R. Trucchio maintains uniQure with a Buy and lowers the price target from $110 to $70.

Analyst Upgrades

Chardan Capital Maintains Buy on uniQure, Lowers Price Target to $53

Chardan Capital analyst Daniil Gataulin maintains uniQure with a Buy and lowers the price target from $76 to $53.

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.